34 related articles for article (PubMed ID: 3501548)
1. The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma.
Canellos GP; Skarin AT; Klatt MM; Rosenthal DS; Case DC; Pinkus GS; Jochelson MS; Yeap BY; Shipp MA
Semin Hematol; 1987 Apr; 24(2 Suppl 1):2-7. PubMed ID: 2438777
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies.
Anderson KC; Skarin AT; Rosenthal DS; MacIntyre JM; Pinkus GS; Case DC; Leonard RC; Canellos GP
Cancer Treat Rep; 1984 Nov; 68(11):1343-50. PubMed ID: 6209007
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin's lymphoma of unfavorable histology.
Canellos GP; Skarin AT; Rosenthal DS; Moloney WC; Frei E
Cancer Treat Rep; 1981; 65 Suppl 1():125-9. PubMed ID: 6173118
[TBL] [Abstract][Full Text] [Related]
4. [Comparing CHOP, CHOP+HD-MTX,and BFM-90 regimens in the survival rate of children and adolescents with B cell non-Hodgkin's lymphoma].
Sun XF; Su YS; Liu DG; Jiang WQ; He YJ; Lin TY; Huang HQ; Zhang L; Xia ZJ; Li YH; Zhou ZM; Chen XQ; Xia Y; Zhen ZJ; Guan ZZ
Ai Zheng; 2004 Aug; 23(8):933-8. PubMed ID: 15301718
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate-leucovorin factor rescue regimens in diffuse large cell lymphoma.
Skarin AT; Canellos GP
NCI Monogr; 1987; (5):71-6. PubMed ID: 3501548
[TBL] [Abstract][Full Text] [Related]
6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
7. [Chemotherapy for non-Hodgkin's lymphoma].
Kuraishi Y; Usui N; Dobashi N
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2210-6. PubMed ID: 9881077
[TBL] [Abstract][Full Text] [Related]
8. Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial.
Browman GP; Goodyear MD; Levine MN; Russell R; Archibald SD; Young JE
J Clin Oncol; 1990 Feb; 8(2):203-8. PubMed ID: 2405105
[TBL] [Abstract][Full Text] [Related]
9. High-dose methotrexate: a critical reappraisal.
Ackland SP; Schilsky RL
J Clin Oncol; 1987 Dec; 5(12):2017-31. PubMed ID: 3316519
[TBL] [Abstract][Full Text] [Related]
10. How long can folinic acid rescue be delayed after high-dose methotrexate without toxicity?
Cohen IJ; Wolff JE
Pediatr Blood Cancer; 2014 Jan; 61(1):7-10. PubMed ID: 24038885
[TBL] [Abstract][Full Text] [Related]
11. Concepts in use of high-dose methotrexate therapy.
Treon SP; Chabner BA
Clin Chem; 1996 Aug; 42(8 Pt 2):1322-9. PubMed ID: 8697606
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
